Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma - Trial NCT06008106
Access comprehensive clinical trial information for NCT06008106 through Pure Global AI's free database. This Phase 3 trial is sponsored by Shanghai Kechow Pharma, Inc. and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 165 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Kechow Pharma, Inc.
Timeline & Enrollment
Phase 3
Sep 22, 2023
Sep 22, 2027
Primary Outcome
Progression-free Survival(PFS)
Summary
This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to
 evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination
 chemotherapy of investigator's choice in advanced melanoma patients with NRAS mutation who
 have received immunotherapy before. Subjects were stratified according to the baseline
 lactate dehydrogenase level and chemotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06008106
Non-Device Trial